US 11,986,516 B2
Compositions and methods for treatment of SARS-COV-2
Michelle Lorraine Rivera, Charlotte, NC (US)
Assigned to Phenom Pharmaceuticals, LLC, Miami Beach, FL (US)
Filed by Phenom Pharmaceuticals, LLC, Miami Beach, FL (US)
Filed on Jan. 27, 2023, as Appl. No. 18/160,950.
Application 18/160,950 is a continuation of application No. PCT/US2022/073456, filed on Jul. 6, 2022.
Claims priority of provisional application 63/234,949, filed on Aug. 19, 2021.
Prior Publication US 2023/0302101 A1, Sep. 28, 2023
Int. Cl. A61K 38/48 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61P 31/14 (2006.01)
CPC A61K 38/4813 (2013.01) [A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 31/14 (2018.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating a subject infected with or at risk of being infected with a coronavirus, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising:
(a) a recombinant angiotensin converting enzyme 2 (rACE-2) protein that specifically binds to a coronavirus protein, wherein the rACE-2 protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2;
(b) a cellulose derivative selected from hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), or a combination thereof; and
(c) an excipient selected from a glycol alcohol, a sugar alcohol, an acid, an ester, or any combination thereof, wherein the rACE-2 protein is at a concentration of about 2 percent weight/weight (w/w).